Table 1.

Liver and kidney structural parameters before and after 6 months of treatment with octreotide or placebo according to treatment sequence and in the study group as a wholea

ParameterBaselinePlaceboOctreotide
BeforeAfterBeforeAfter
Octreotide first (n = 5)
    liver volumes
        total, ml1375 ± 1861440 ± 1881443 ± 1701375 ± 186
        cyst, ml32 ± 3832 ± 4130 ± 3832 ± 38
        parenchyma, ml1343 ± 2011400 ± 1881413 ± 1921343 ± 201
    kidney volumes
        total, ml1877 ± 3391987 ± 4091816 ± 2421877 ± 339
        cyst, ml1176 ± 3031243 ± 3431115 ± 2651176 ± 303
        parenchyma, ml220 ± 64233 ± 78222 ± 60220 ± 64
Placebo first (n = 7)
    liver volumes
        total, ml1726 ± 5931704 ± 6051704 ± 6051631 ± 567
        cyst, ml131 ± 186131 ± 182131 ± 182136 ± 196
        parenchyma, ml1596 ± 5431573 ± 5511573 ± 5511495 ± 509
    kidney volumes
        total, ml2878 ± 10603076 ± 1106c3076 ± 11063155 ± 1181
        cyst, ml1999 ± 9282134 ± 980c2134 ± 9802194 ± 1029
        parenchyma, ml257 ± 61264 ± 70264 ± 70249 ± 68
Whole sample (n = 12)
    liver volumes
        total, ml1608 ± 4731580 ± 4871594 ± 4801595 ± 4781524 ± 453b
        cyst, ml89 ± 14989 ± 14889 ± 14689 ± 14693 ± 156
        parenchyma, ml1519 ± 4281490 ± 4391504 ± 4331506 ± 4311432 ± 403b
    kidney volumes
        total, ml2435 ± 9662461 ± 9592623 ± 1021b2551 ± 10532622 ± 1111c
        cyst, ml1631 ± 8381656 ± 8261762 ± 882b1709 ± 9081770 ± 941
        parenchyma, ml242 ± 61242 ± 62251 ± 72247 ± 67237 ± 65
  • a Baseline data in the whole cohort are independent of treatment sequence, and data are presented as mean ± SD.

  • b P < 0.005 versus start at Wilcoxon test for paired observations.

  • c P < 0.05 versus start at Wilcoxon test for paired observations.